Zentalis Pharmaceuticals, Inc. Defined Contribution Plan, Cost
Zentalis Pharmaceuticals, Inc. (ZNTL) reported Defined Contribution Plan, Cost of $1.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-26
- Zentalis Pharmaceuticals, Inc. defined contribution plan, cost for fiscal 2025 was $1.40M, a 17.65% decline from fiscal 2024.
- Zentalis Pharmaceuticals, Inc. defined contribution plan, cost for fiscal 2024 was $1.70M, a 13.33% increase from fiscal 2023.
- Zentalis Pharmaceuticals, Inc. defined contribution plan, cost for fiscal 2023 was $1.50M, a 7.14% increase from fiscal 2022.
- Zentalis Pharmaceuticals, Inc. defined contribution plan, cost for fiscal 2022 was $1.40M, a 40.00% increase from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 12 month | Defined Contribution Plan, Cost 12 month as first filed |
|---|---|---|
| 2025-12-31 | $1.40M 10-K · filed 2026-03-26 | |
| 2024-12-31 | $1.70M 10-K · filed 2026-03-26 | |
| 2023-12-31 | $1.50M 10-K · filed 2026-03-26 | |
| 2022-12-31 | $1.40M 10-K · filed 2025-03-26 | |
| 2021-12-31 | $1.00M 10-K · filed 2024-02-27 | $991.50K 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |